Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 263.55B P/E 35.15 EPS this Y 0.70% Ern Qtrly Grth -66.80%
Income 4.82B Forward P/E 13.52 EPS next Y 9.30% 50D Avg Chg 8.00%
Sales 54.32B PEG 4.82 EPS past 5Y 8.87% 200D Avg Chg -1.00%
Dividend 4.00% Price/Book 19.85 EPS next 5Y 3.28% 52W High Chg -11.00%
Recommedations 2.20 Quick Ratio 0.63 Shares Outstanding 1.77B 52W Low Chg 14.00%
Insider Own 0.15% ROA 8.07% Shares Float 1.76B Beta 0.54
Inst Own 72.09% ROE 35.20% Shares Shorted/Prior 13.72M/12.08M Price 149.38
Gross Margin 69.21% Profit Margin 8.95% Avg. Volume 5,937,400 Target Price 179.25
Oper. Margin 31.81% Earnings Date Apr 25 Volume 5,753,546 Change 0.57%
About AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine with or without aura in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

ABBV Chatroom

User Image FrnkTss Posted - 6 hours ago

$ABBV channeling here https://youtu.be/TW37lm5AhwA

User Image TongaGuy Posted - 19 hours ago

$ABBV Don't give your shares away! Hold them! The big boys aren't looking to make a few dollars per share. Remember the ultimate goal... https://www.amazon.com/Blood-Money-Billionaires-Biotech-Blockbuster/dp/B0BRYJVS23/ref=sr_1_1?&_encoding=UTF8&tag=spdohgoi-20&linkCode=ur2&linkId=a6655008e34440f79bf8c8d21fada065&camp=1789&creative=9325

User Image Dr_Feel_Good Posted - 1 day ago

@RoundAssRousey agreed - went heavy during Covid and bought between $20-30/share when the divvy was nearly 7%. It deserves to be a staple in every portfolio for both growth and cash flow. I consider it a dividend aristocrat name with the likes of $ABBV.

User Image freshnotfrozen Posted - 2 days ago

$ABBV She wants a bite of the apple again. Look out Apple Hasn’t happened in a few years. The magis cross, lol

User Image seasonal13 Posted - 2 days ago

$ABBV monster

User Image PanicSeller8 Posted - 2 days ago

$ABBV New all time high today looks possible.

User Image resume777 Posted - 2 days ago

$ATNM easy to connect the dots. $ATNM can treat AML patients better. Bone Marrow Transplants cure AML $BMS can't treat non-eligible AML bone-marrow transplants with QUAZAR AML-001 $ABBV can't treat AML TP53 mutations with VENCLEXTA $ATNM can "bridge" non-eligible AML to bone-marrow transplants and can treat AML TP53 mutations with AVCURI (131I-apamistimab; Iomab-B) Big pharma ($BMS, $NVS) has 2024 investment interest in radiotherapies. $ATNM BLA 1H24.

User Image resume777 Posted - 2 days ago

@EFhutton420 something tells me these people attending the conference along with the 8600+ in-person and virtual attendees who actually treat patients care. $BMY $NVS $ABBV ' thanks for the laugh this morning.

User Image freshnotfrozen Posted - 2 days ago

$ABBV It hasn’t caught Apple in a minute… But its gonna happen again

User Image ElmerFuddz Posted - 3 days ago

$TARS $ABBV gearing up for M&A…lot of former ABBV executives and sales folks here at Tarsus. It fits their profile. 😍

User Image crtlabz Posted - 3 days ago

$ABBV nice reversal

User Image resume777 Posted - 3 days ago

@greencheese500 @buynhold1 the beauty of the AbbVie conversation will further come to light on Saturday at the Tandem Meetings, when the medical community becomes more aware of Iomab-B. $BMY Bristol has a large presence at the Tandem conference and already acquired an Ac-225 manfucturing source (RayzeBio). To me, the contenders now are $ABBV, $BMY, and $NVS.

User Image resume777 Posted - 3 days ago

@greencheese500 @buynhold1 Does AbbVie $ABBV aquire $ATNM thus getting rid of the TP53 mutation resistance of Venetoclax and gaining patent rights with Venetoclax+alpha-emitting isotope combos?https://pubmed.ncbi.nlm.nih.gov/33347715/the $ABBV has Venetoclax, the current preferred AML treatment. $ABBV said they can't overcome and are still in pre-clinical theory with inhibitor alternatives to TP53 mutations. https://pubmed.ncbi.nlm.nih.gov/34255353/ https://ashpublications.org/blood/article/142/Supplement%201/2927/501419/Targeting-Venetoclax-Resistance-in-TP53-Mutated $ATNM has shown Actimab-A and Iomab-B can overcome TP53 mutations and $ATNM has the patent to alpha-emitting isotope + Bcl-2 inhibitors (e.g. Venetoclax). https://patents.justia.com/patent/11844799 To me, this sounds like AbbVie has much to gain if they want to protect their AML drug market. Alternatively, $NVS is still on the hunt for radioligand investments.

User Image Stock_Titan Posted - 3 days ago

$ABBV Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity https://www.stocktitan.net/news/ABBV/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-4nbrnyk0qe2w.html

User Image Stock_Titan Posted - 3 days ago

$ABBV AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology https://www.stocktitan.net/news/ABBV/abb-vie-and-tentarix-announce-collaboration-to-develop-conditionally-78n80ia0omp0.html

User Image swingingtech Posted - 3 days ago

$ABBV $CERE https://wallstreetwaves.com/is-abbvie-stock-a-buy-now/

User Image dallas095 Posted - 4 days ago

$IOVA $ABBV sold 13B bond , raise money for acquisitions, who ? Could be iova, 13B , almost 50$/ share

User Image TheBiotechInvestor_ Posted - 4 days ago

$ABBV maybe acquire Vanda ? https://youtu.be/K1JIjwA6_Uk?si=CnaQaV8Kr1onj-r-

User Image RainbowTrump Posted - 4 days ago

$ABBV how long will it take to make the bond offering?? $XBI

User Image DonCorleone77 Posted - 4 days ago

$ABBV AbbVie targeting bond offering of at least $13B for M&A, Bloomberg says

User Image BenjiBulls Posted - 4 days ago

$PMN ready to pop $BMY $GSK $MRK $ABBV

User Image swingingtech Posted - 4 days ago

$ABBV $PBYI $ACIU $CERE. https://wallstreetwaves.com/abbvie-abbv-announces-appointment-of-new-ceo-robert-michael/

User Image Inforce Posted - 4 days ago

$IOVA Look at the recent acquisition of Immunogen with their ADC drug approval. They got bought out quickly by $ABBV.

User Image Stock_Titan Posted - 4 days ago

$ABBV BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs https://www.stocktitan.net/news/ABBV/botox-r-cosmetic-onabotulinumtoxin-a-announces-its-2024-grant-2t59f2gbnz98.html

User Image RonaldAnderson366 Posted - 5 days ago

$ABBV is a giant in immunology, yet COEP's strategic partnerships are accelerating the development of novel cell therapies for cancer.

User Image abqbob Posted - 5 days ago

$ABBV Mr Gonzales has been great for ABBV and we appreciate all his leadership thank you

User Image Ampflipz Posted - 5 days ago

$ABBV I love the support and positivity on this forum. I assume most people would be in a good mood if they held onto a winning company like AbbVie.

User Image Stocksrunner Posted - 5 days ago

💼 $ABBV Executive Shakeup 🔄 AbbVie Inc. undergoes a leadership transition as CEO Richard Gonzalez steps down on July 1. President and COO Robert Michael steps into the role of CEO, while Gonzalez assumes the position of Executive Chairman. How will this change impact the pharmaceutical giant's future strategies? Stay tuned for expert insights and market reactions! 💊 https://stocksrunner.com/symbol/ABBV

User Image UltraInstinct Posted - 5 days ago

$ABBV What a strong stock this is..

User Image tradethehalt Posted - 5 days ago

$ABBV AbbVie Appoints Robert A. Michael as New CEO, Replacing Richard Gonzalez. https://www.marketwatch.com/story/abbvie-taps-new-ceo-as-it-faces-fresh-competition-for-blockbuster-drug-humira-67b7bcbd

Analyst Ratings
Truist Securities Buy Feb 6, 24
Raymond James Outperform Feb 6, 24
BMO Capital Outperform Feb 5, 24
Raymond James Outperform Feb 5, 24
Barclays Overweight Feb 5, 24
William Blair Outperform Jan 29, 24
Barclays Overweight Jan 23, 24
HSBC Hold Dec 18, 23
Goldman Sachs Buy Dec 11, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Donoghoe Nicholas EVP, CHIEF BUS/STRAT.. EVP, CHIEF BUS/STRAT OFFICER Dec 26 Sell 154.72 2,912 450,545 55,903 12/28/23
GONZALEZ RICHARD A CHAIRMAN OF THE BOAR.. CHAIRMAN OF THE BOARD AND CEO Jul 31 Sell 148.87 78,500 11,686,295 565,294 08/02/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Apr 17 Sell 161.84 7,499 1,213,638 35,330 04/19/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 28 Sell 155 15,003 2,325,465 42,829 03/02/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 28 Option 93.5 15,003 1,402,780 57,832 03/02/23
Siatis Perry C EVP, GC AND SECRETAR.. EVP, GC AND SECRETARY Feb 28 Sell 153.22 12,135 1,859,325 10,377 03/02/23
Strom Carrie C SVP & PRES GLOBAL AL.. SVP & PRES GLOBAL ALLERG AESTH Feb 16 Sell 151.02 28,541 4,310,262 37,921 02/21/23
Strom Carrie C SVP & PRES GLOBAL AL.. SVP & PRES GLOBAL ALLERG AESTH Feb 16 Option 62.09 14,179 880,374 66,462 02/21/23
SALEKI-GERHARDT AZITA EVP, OPERATIONS EVP, OPERATIONS Feb 16 Option 51.42 25,000 1,285,500 258,208 02/21/23
SALEKI-GERHARDT AZITA EVP, OPERATIONS EVP, OPERATIONS Feb 16 Sell 149.59 25,000 3,739,750 233,208 02/21/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 16 Sell 151.02 15,321 2,313,777 62,679 02/21/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 16 Option 105.92 15,321 1,622,800 78,000 02/21/23
SEVERINO MICHAEL Vice Chairman Vice Chairman May 23 Option 104.59 79,801 8,346,387 231,904 05/25/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 23 Sell 151.16 79,801 12,062,719 152,103 05/25/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer May 16 Option 54.86 83,960 4,606,046 125,583 05/20/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer May 16 Sell 155 83,960 13,013,800 41,623 05/20/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 16 Option 78.23 200,000 15,646,000 252,103 05/18/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 16 Sell 154.58 200,000 30,916,000 152,103 05/18/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 06 Sell 151.2 300,000 45,360,000 152,103 05/10/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 06 Option 57.21 300,000 17,163,000 252,103 05/10/22
Stewart Jeffrey Ryan EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 24 Option 58.88 27,690 1,630,387 88,631 03/25/22
Stewart Jeffrey Ryan EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 24 Sell 159.2 27,690 4,408,248 60,941 03/25/22
Durkin Brian L VP, Controller VP, Controller Mar 09 Option 79.02 11,682 923,112 37,722 03/11/22
Durkin Brian L VP, Controller VP, Controller Mar 09 Sell 150 18,628 2,794,200 19,094 03/11/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer Mar 01 Sell 148.12 25,000 3,703,000 16,623 03/02/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer Feb 25 Sell 148.43 15,000 2,226,450 41,623 03/01/22
Michael Robert A. Vice Chairman Vice Chairman Feb 25 Sell 148.32 43,105 6,393,334 37,877 03/01/22
Strom Carrie C SVP & Pres Global Al.. SVP & Pres Global Allerg Aesth Feb 07 Sell 141.17 2,396 338,243 42,499 02/08/22
AUSTIN ROXANNE S Director Director Nov 02 Sell 116.42 71,844 8,364,078 49,284 11/04/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Aug 25 Sell 120 13,080 1,569,600 11,595 08/25/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Aug 25 Option 114.36 7,080 809,669 18,675 08/25/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Feb 24 Option 86.26 20,195 1,742,021 52,946 02/24/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Feb 24 Sell 105 20,195 2,120,475 32,751 02/24/21
RICHMOND TIMOTHY J. EVP, Chief HR Office.. EVP, Chief HR Officer Dec 01 Option 51.42 51,990 2,673,326 51,990 12/01/20
RICHMOND TIMOTHY J. EVP, Chief HR Office.. EVP, Chief HR Officer Dec 01 Sell 105 51,990 5,458,950 12/01/20
SALEKI-GERHARDT AZITA EVP, Operations EVP, Operations Nov 12 Option 24.21 4,800 116,208 118,667 11/12/20
SALEKI-GERHARDT AZITA EVP, Operations EVP, Operations Nov 12 Sell 93.61 4,800 449,328 113,867 11/12/20
GONZALEZ RICHARD A Chairman of the Boar.. Chairman of the Board and CEO Nov 12 Option 56.87 194,154 11,041,538 512,796 11/12/20
GONZALEZ RICHARD A Chairman of the Boar.. Chairman of the Board and CEO Nov 12 Sell 96.76 231,604 22,410,003 318,642 11/12/20